10-Q: AIBiotics Therapies Reports Q1 2025 Results: Revenue Emerges, Losses Persist Amid Going Concern Uncertainty
Sentiment:
Quarterly Report
AIBiotics Therapies reports its Q1 2025 results, highlighting the emergence of revenue alongside continued net losses and concerns about its ability to operate as a going concern.
Capital raiseThe company is actively pursuing additional equity financing through discussions with investment bankers and private investors.Management expects the Company to continue to fund its operations primarily through the issuance of debt or equity.
Worse than expectedThe company's net loss increased from $425,942 to $591,397 compared to the same period last year.The company's working capital deficit increased from $4,666,666 to $4,944,635 compared to the end of last year.The company's auditors have raised substantial doubt about its ability to continue as a going concern.
Summary
- AIBiotics Therapies, Inc. filed its Form 10-Q for the quarter ended March 31, 2025.
- The company reported revenue of $2,183 for the three months ended March 31, 2025, compared to no revenue for the same period in 2024.
- The net loss for the quarter was $591,397, compared to a net loss of $425,942 for the three months ended March 31, 2024.
- General and administrative expenses increased by 47% to $531,647.
- As of March 31, 2025, the company had $156,737 in cash and cash equivalents.
- The company has a working capital deficit of $4,944,635.
- There is substantial doubt about the company's ability to continue as a going concern.
- The company is pursuing additional equity financing to improve its liquidity.
Sentiment
Score: 3
Explanation: The sentiment is negative due to the increasing net loss, significant working capital deficit, and going concern uncertainty, despite the emergence of revenue.
Positives
- The company generated revenue of $2,183 in Q1 2025, compared to no revenue in the same period last year.
- Interest expense decreased by $3,137, or 5%, from $65,070 to $61,933.
- The company is actively pursuing additional equity financing.
Negatives
- The company incurred a net loss of $591,397 for the three months ended March 31, 2025.
- The company has a significant working capital deficit of $4,944,635.
- The company's auditors have raised substantial doubt about its ability to continue as a going concern.
- The company's convertible notes payable are currently in default.
Risks
- The company's ability to continue as a going concern is uncertain.
- The company is dependent on raising additional capital.
- The company has a history of operating losses and negative cash flows.
- The company's convertible notes payable are currently in default.
- The company's disclosure controls and procedures were not effective at the reasonable assurance level as of March 31, 2025.
Future Outlook
The company plans to fund its operations with its cash on hand and additional financing.
Industry Context
Without more information about AIBiotics' specific industry and competitors, it's difficult to provide a detailed industry context. However, the company's focus on developing its business and raising capital is common for early-stage companies in growth-oriented sectors.
Related Party Transactions
- The company has a consulting agreement with its CEO, Benjamin Kaplan, with accrued expenses of $936,000 as of March 31, 2025.
- The company has notes payable to a major shareholder, Lender F, with an outstanding balance of $168,370 as of March 31, 2025.
- The company has accrued expenses from board compensation of $150,000 as of March 31, 2025.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
- Employees' jobs are at risk if the company cannot secure additional funding and improve its financial performance.
- Creditors face the risk of not being repaid if the company is unable to continue as a going concern.
Next Steps
- The company is actively pursuing additional equity financing.
- Management is devoting substantially all of its efforts to developing its business.
Key Dates
| Date | Description |
|---|---|
| 2000-01-21 | Company incorporated in Nevada as RM Investors, Inc. |
| 2020-12 | Entered into definitive agreements with Ehave, Inc. and AIBiotics Therapies Inc. |
| 2021-01-19 | Transaction with Ehave, Inc. closed, resulting in a reverse merger. |
| 2021-08-27 | Issued a convertible note payable to Lender A. |
| 2021-09-17 | Issued a convertible note payable to Lender B. |
| 2021-10-27 | Issued a convertible note payable to Lender C. |
| 2021-11-17 | Entered into an Executive Consulting Agreement with Benjamin Kaplan. |
| 2022 | Company received notice to convert three notes into shares of the Company's common stock. |
| 2022 | Company entered into a consulting agreement whereby the consultant agreed to act as a medical advisor to the Company for certain services. |
| 2024-01-30 | Signed an agreement with a major shareholder for a $165,000 note payable. |
| 2024-05-29 | Company signed a consulting agreement with a consultant. |
| 2024-06-24 | Board of Directors approved the designation of one share of preferred stock as Series A Preferred Stock. |
| 2024-06-24 | Board of Directors approved an increase in the authorized shares of common stock from 100,000,000 to 467,000,000. |
| 2024-07-15 | Company adopted the AIBiotics, Inc. limits the number of shares that may be issued pursuant to the 2024 Plan to 50,000,000 shares of common stock. |
| 2024-07-29 | Company entered into an Exchange Agreement with Ehave, Inc. |
| 2024-09-23 | Company issued 378,582 shares of common stock to settle $26,250 of accrued expenses related to the consulting agreement. |
| 2024-11-17 | The Company created a new Florida-based subsidiary, NPD Genius, LLC (NPD). |
| 2024-11-28 | Company entered into an asset sale and purchase agreement with Philon Labs, LLC. |
| 2025-02-03 | Mycotopia Therapies, Inc. amended its articles of incorporation to change its name to Aibotics Inc. |
| 2025-03-31 | End of the quarterly period. |
| 2025-05-16 | Date shares of common stock outstanding were calculated. |
| 2025-05-19 | Date of report signature. |
Keywords
financial statements, Form 10-Q, AIBiotics Therapies, going concern, net loss, revenue, liquidity, financing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.